Agilent Technologies (NYSE: A) and Viveve Medical (NASDAQ:VIVE) are both computer and technology companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation.
Insider & Institutional Ownership
40.2% of Viveve Medical shares are owned by institutional investors. 35.1% of Viveve Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This is a summary of current ratings and recommmendations for Agilent Technologies and Viveve Medical, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Agilent Technologies currently has a consensus target price of $70.59, suggesting a potential upside of 5.52%. Viveve Medical has a consensus target price of $10.00, suggesting a potential upside of 173.22%. Given Viveve Medical’s stronger consensus rating and higher possible upside, analysts plainly believe Viveve Medical is more favorable than Agilent Technologies.
Agilent Technologies pays an annual dividend of $0.60 per share and has a dividend yield of 0.9%. Viveve Medical does not pay a dividend. Agilent Technologies pays out 101.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Agilent Technologies has increased its dividend for 2 consecutive years.
Earnings and Valuation
This table compares Agilent Technologies and Viveve Medical’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Agilent Technologies||$4.47 billion||4.82||$684.00 million||$0.59||113.39|
|Viveve Medical||$15.29 million||7.48||-$36.95 million||($2.14)||-1.71|
Agilent Technologies has higher revenue and earnings than Viveve Medical. Viveve Medical is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.
This table compares Agilent Technologies and Viveve Medical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
Agilent Technologies has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, Viveve Medical has a beta of -0.79, indicating that its share price is 179% less volatile than the S&P 500.
Agilent Technologies beats Viveve Medical on 11 of the 17 factors compared between the two stocks.
About Agilent Technologies
Agilent Technologies, Inc. provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business. Its life sciences and applied markets business segment offers instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular level. Its diagnostics and genomics business segment includes the reagent partnership, pathology, companion diagnostics, genomics and the nucleic acid solutions businesses. Its Agilent CrossLab business segment spans the entire lab with its consumables and services portfolio.
About Viveve Medical
Viveve Medical, Inc. designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories. Physicians attach the single-use treatment tip to the handpiece, which is connected to the console. The generator authenticates the treatment tip and programs the system for the desired treatment without further physician intervention. The treatment is performed in a physician’s office, in less than 30 minutes, and does not require the use of anesthesia. Geneveve is indicated for use in general surgical procedures for electrocoagulation and hemostasis in the United States.
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.